The Valley Desk

Healthcare research from Johnson & Johnson, page 2

A filtered view. Show the full list.

Refine

817 publications and 7 software projects · listings 25–48

Listings

  1. ArticlePregnancy (Hoboken, N.J.)

    Characterization of the clinical course of early-onset severe hemolytic disease of the fetus and newborn

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Disease researchAdded

  2. ArticleCPT: pharmacometrics & systems pharmacology

    Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  3. ArticleCPT: pharmacometrics & systems pharmacology

    MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  4. ArticleCPT: pharmacometrics & systems pharmacology

    Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  5. EditorialCPT: pharmacometrics & systems pharmacology

    Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  6. ArticlePharmaceutical statistics

    Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  7. ArticlePulmonary circulation

    Time to Therapy Activation and Initial Combination Therapy (TITANIC) for Patients With Pulmonary Arterial Hypertension

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  8. ArticlePulmonary circulation

    Use of Machine-Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  9. ArticleStatistics in medicine

    Informative Futility Rules Based on Conditional Assurance

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  10. ArticleAnalytical and bioanalytical chemistry

    Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Disease researchAdded

  11. Clinical trial reportCancer immunology, immunotherapy : CII

    A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  12. Clinical trial reportCancer immunology, immunotherapy : CII

    A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  13. Clinical trial reportCancer chemotherapy and pharmacology

    A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer

    Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

    Clinical careAdded

  14. Clinical trial reportJournal of neurology

    Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  15. Clinical trial reportJournal of neurology

    Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  16. ArticlePharmaceutical research

    Investigation into Clearance of Organic Compounds from Biomanufacturing Process Streams during Ultrafiltration/Diafiltration

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Biomedical and life sciencesAdded

  17. ArticleTargeted oncology

    Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics

    Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source

    Clinical careAdded

  18. ReviewAdvances in therapy

    Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  19. ArticleAdvances in therapy

    Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  20. ArticleAdvances in therapy

    FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  21. ArticleAdvances in therapy

    Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Public healthAdded

  22. ArticleAdvances in therapy

    Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  23. ArticleAdvances in therapy

    BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded

  24. ReviewAdvances in therapy

    Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits

    Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

    Clinical careAdded